Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Expert Answers to Questions on PARP Inhibitor Combinations in Prostate Cancer

In this podcast episode, listen to Wassim Abida, MD, PhD; Joaquin Mateo, MD, PhD; and Charles J. Ryan, MD, as they answer questions on the use of PARP inhibitors and PARP inhibitor combinations for patients with prostate cancer.
Charles J. Ryan, MD
Program Director
person default
Wassim Abida, MD, PhD
Joaquin Mateo, MD, PhD
Released: June 30, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Merck Sharp & Dohme Corp.
Pfizer, Inc.

Related Content

Slides from Clinical Care Options (CCO) on 2021 treatment recommendations for patients with nmCRPC.

David F. Penson, MD Released: September 10, 2021

Slides from Clinical Care Options (CCO) on best practices in classifying prostate cancer and using ADT

Daniel W. Lin, MD Released: September 10, 2021

Slides from Clinical Care Options (CCO) on 2021 treatment recommendations for patients with mHSPC.

Alicia K. Morgans, MD, MPH Released: September 10, 2021

Daniel P. Petrylak, MD, and Elizabeth R. Plimack, MD, MS, review key data in genitourinary cancers from the 2021 ASCO Annual Meeting, as reported by Clinical Care Options (CCO)

Daniel P. Petrylak, MD Elizabeth R. Plimack, MD, MS Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: September 7, 2021 Expired: September 6, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue